Page last updated: 2024-09-05

s 16020-2 and Colonic Neoplasms

s 16020-2 has been researched along with Colonic Neoplasms in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Alvord, WG; Gray-Goodrich, M; Jeffers, M; Kohlhagen, G; Koo, HM; McWilliams, MJ; Monks, A; Paull, KD; Pommier, Y; Vaigro-Wolff, A; Vande Woude, GF1
Atassi, G; Burbridge, MF; Guilbaud, N; Jan, M; Kraus-Berthier, L; Pierré, A; Rouillon, MH; Saint-Dizier, D1

Other Studies

2 other study(ies) available for s 16020-2 and Colonic Neoplasms

ArticleYear
The ras oncogene-mediated sensitization of human cells to topoisomerase II inhibitor-induced apoptosis.
    Journal of the National Cancer Institute, 1999, Feb-03, Volume: 91, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Carbazoles; Colonic Neoplasms; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Genes, ras; Humans; Mutation; Phenotype; Pyridines; Topoisomerase II Inhibitors; Transfection; Tumor Cells, Cultured

1999
Experimental antitumour activity of S 16020-2 in a panel of human tumours.
    European journal of cancer (Oxford, England : 1990), 1997, Volume: 33, Issue:11

    Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Colonic Neoplasms; Doxorubicin; Drug Screening Assays, Antitumor; Ellipticines; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured

1997